We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go: Stretch investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Integumen is a personal health company developing and commercialising technology and products for the human integumentary system that may improve physical appearance, hygiene and general health outcomes.
days to go: Expired investment: £2,160,000
Run3D is a biotechnology company that has developed a 3D gait analysis system with the aim to help people identify injuries, deliver better performance, and make better running decisions. 3D gait analysis involves using infrared cameras to track positions of small reflective markers attached to a person in motion, capturing measurable data to help quantify a person's risk of injury, biomechanical efficiency, performance, footwear, and recommend proper diagnosis where necessary. The company plans to use the investment to grow its business.
days to go: Expired investment: Withheld
Doctaly is  the brand new healthcare platform providing the quickest way to find and book an affordable, face-to-face, same day GP appointment. Choose from their trusted private doctors, at a convenient time and location from just £39.99.
days to go: Expired investment: £807,580
Intelligent Health aim to get the whole community active by providing games and incentives such as ''beat the street''. By providing schools and communities with friendly competition to walk and cycle more by tapping their cards on ''beat boxes'', and with prizes and league tables on offer, Intelligent health are bringing communities together. 
days to go: Expired investment: £700,000
The Studio enable members to achieve results through sustainable, structured training. The Studio offer a whole range of sessions such as group classes, one-to-one personal training, spinning and yoga.   
days to go: Expired investment: £30,564
Future You Cambridge is a company that sells clinically proven health supplements directly to consumers. Since its launch in 2016, it has sold products to over 100,000 customers. The company's Lactolycopene product received a patent in December 2017 and its Fertility+ product was also covered by the European Journal of Nutrition in a clinical paper and was shown to have resulted in a 40% increase in male fertility. The company's offerings now stand at 24 products, including the popular CBD product and its first product for pets, Curcupet-K9. Additionally, the company won the 2018 Cambridge Service Excellence and Independent High Growth Business of the Year Awards and has 5-star ratings on Trustpilot. They will use the investment to scale up direct advertising campaigns, expand its product range by more than 10 new products, and invest in their website to make it more intuitive.

Pitch Rated

67%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £655,011
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph